Skip to main content

Table 5 Association between histological active inflammation and clinical characteristics

From: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

Characteristic Active inflammation
N = 129
No-active inflammation
N = 53
P value
Time from ICPI to onset (months, SD) 3 (4) 5 (9) 0.014
Duration of symptoms (days, SD) 39 (96) 17 (21) 0.102
Diarrhea grade, n (%)    0.001
 1 9 (7.0) 15 (28.3)  
 2 43 (33.3) 17 (32.1)  
 3–4 77 (59.7) 21 (39.6)  
Colitis grade, n (%)    0.012
 1 19 (14.7) 18 (34.0)  
 2 63 (48.8) 23 (43.4)  
 3–4 47 (36.4) 12 (22.6)  
IV steroids, n (%) 71 (54.0) 13 (24.5) < 0.001
Duration of steroid (days, SD) 67 (77) 37 (34) 0.083
Infliximab/vedolizumab, n (%) 39 (33.6) 3 (12.0) 0.032
Colonoscopy findings, n (%)    < 0.001
 Ulcer 49 (38.0) 0 (0.0)  
 Non-ulcerative inflammation 51 (39.5) 15 (28.3)  
 Normal 29 (22.5) 38 (71.7)  
High-risk endoscopic features, n (%) 63 (48.8) 8 (15.1) < 0.001
Outcomes, n (%)    
 Hospitalization 98 (76.0) 34 (64.2) 0.143
 Duration of hospitalization (days, SD) 8 (6) 6 (8) 0.196
 ICU admission 2 (1.6) 5 (9.4) 0.023
 Recurrence 44 (34.1) 7 (13.2) 0.004
 Repeat endoscopy 32 (24.8) 4 (7.5) 0.007
  1. Abbreviation: ICPI immune checkpoint inhibitor, ICU intensive care unit, IV intravenous, SD standard deviation